September 3, 2024 03:43 PM EDT

Researchers seek answers as they spell out Phase 3 failure of Bayer’s next-gen anticoagulant

Lei Lei Wu

News Reporter

Researchers reported Sunday that atrial fibrillation patients who received Bayer’s experimental anticoagulant were significantly more likely to experience a stroke or systemic embolism compared to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Researchers seek answers as they spell out Phase 3 failure of Bayer’s next-gen anticoagulant

Lei Lei Wu

News Reporter

Sign up to read this article for free.

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Scorpion details early data on targeted breast cancer drug as it seeks to challenge Novartis, Roche

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

Updated: Bristol Myers touts LAG-3 strategy in lung cancer but data caveats dampen excitement

Post-Hoc: Big promises built Moderna. They might also be its undoing

Re­searchers seek an­swers as they spell out Phase 3 fail­ure of Bay­er’s next-gen an­ti­co­ag­u­lant

Lei Lei Wu

News Reporter

Sign up to read this article for free.

more like this

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

Scor­pi­on de­tails ear­ly da­ta on tar­get­ed breast can­cer drug as it seeks to chal­lenge No­var­tis, Roche

Ar­bor Biotech­nolo­gies cuts ear­ly-stage dis­cov­ery work, lays off staff

Up­dat­ed: Bris­tol My­ers touts LAG-3 strat­e­gy in lung can­cer but da­ta caveats damp­en ex­cite­ment

Post-Hoc: Big promis­es built Mod­er­na. They might al­so be its un­do­ing

Researchers seek answers as they spell out Phase 3 failure of Bayer’s next-gen anticoagulant

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Scorpion details early data on targeted breast cancer drug as it seeks to challenge Novartis, Roche

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

Updated: Bristol Myers touts LAG-3 strategy in lung cancer but data caveats dampen excitement

Post-Hoc: Big promises built Moderna. They might also be its undoing